Details of the Drug

General Information of Drug (ID: DMUL8PZ)

• Drug Name: LNK-754
• Synonyms: LNK 754; 439153-64-7; LNK-754; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-

Indication

Disease Entry	ICD 11	Status	REF
Bladder cancer	2C94	Phase 1	[1]

• Drug Type: Small molecular drug
• Chemical Identifiers:
  Formula: C29H22ClN3O2
  Canonical SMILES: CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC=CC(=C5)C#C)C)O
  InChI: 1S/C29H22ClN3O2/c1-4-19-6-5-7-20(14-19)24-16-28(34)33(3)26-13-10-22(15-25(24)26)29(35,27-17-31-18-32(27)2)21-8-11-23(30)12-9-21/h1,5-18,35H,2-3H3/t29-/m1/s1
  InChIKey: JAHDAIPFBPPQHQ-GDLZYMKVSA-N
• Cross-matching ID:
  PubChem CID: 46208720
  CAS Number: 1190094-64-4
  UNII: L0S47W9GPY
  DrugBank ID: DB12640
  TTD ID: D03BXU

References

• [1] A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors. Clin Cancer Res. 2004 Nov 1;10(21):7127-35.